Immune response to extracellular matrix collagen in chronic hepatitis C–induced liver fibrosis

Brian B. Borg, Anil Seetharam, Vijay Subramanian, Haseeb Ilias Basha, Mauricio Lisker‐Melman, Kevin Korenblat, Christopher D. Anderson, Surendra Shenoy, William C. Chapman, Jeffrey S. Crippin, Thalachallour Mohanakumar – 21 March 2011 – Hepatitis C virus (HCV) infection and its recurrence after orthotopic liver transplantation (OLT) are associated with the remodeling of extracellular matrix (ECM) components [particularly collagen (Col)], which leads to fibrosis.

Anchoring interferon alpha to apolipoprotein A‐I reduces hematological toxicity while enhancing immunostimulatory properties

Jessica Fioravanti, Iranzu González, José Medina‐Echeverz, Esther Larrea, Nuria Ardaiz, Gloria González‐Aseguinolaza, Jesús Prieto, Pedro Berraondo – 21 March 2011 – Interferon alpha (IFNα) is widely used for the treatment of viral hepatitis but substantial toxicity hampers its clinical use. In this work, we aimed at improving the efficacy of IFNα therapy by increasing the IFNα half‐life and providing liver tropism. We selected apolipoprotein A‐I (ApoA‐I) as the stabilizing and targeting moiety.

Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection

Long H. Nguyen, Steve Ko, Shane S. Wong, Pelu S. Tran, Huy N. Trinh, Ruel T. Garcia, Aijaz Ahmed, Glen A. Lutchman, Emmet B. Keeffe, Mindie H. Nguyen – 21 March 2011 – Studies of hepatitis B virus (HBV)/hepatitis C virus (HCV) dual infection are limited. Most are small, conducted outside the United States, and compare dual infection with HCV monoinfection. The goal of this study was to characterize HBV/HCV dual infection in a large multiethnic, matched, case‐control study of dual‐infected and HBV‐monoinfected patients at two United States centers.

Feasibility and safety of percutaneous coronary intervention in patients with end‐stage liver disease referred for liver transplantation

Babak Azarbal, Paul Poommipanit, Boris Arbit, Antoine Hage, Jignesh Patel, Michelle Kittleson, Saibal Kar, Fady M. Kaldas, Ronald W. Busuttil – 21 March 2011 – Percutaneous coronary intervention (PCI) has traditionally not been an option for patients with end‐stage liver disease (ESLD) and coronary artery disease (CAD). This retrospective study was designed to demonstrate the feasibility and safety of PCI in liver transplant candidates. Patients with ESLD and hemodynamically significant CAD who were otherwise deemed to be acceptable candidates for liver transplantation underwent PCI.

Complement component 4d immunostaining in liver allografts of patients with de novo immune hepatitis

Isabel Aguilera, José Manuel Sousa, Francisco Gavilan, Lourdes Gomez, Antonia Álvarez‐Márquez, Antonio Núñez‐Roldán – 21 March 2011 – De novo immune hepatitis (DNIH) is a form of late graft dysfunction after liver transplantation. The fine mechanisms leading to the development of DNIH are not known, and whether this hepatitis is a form of rejection or a result of an auto/alloimmune injury has not been established.

Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9

Marcel Janse, Laetitia E. Lamberts, Lude Franke, Soumya Raychaudhuri, Eva Ellinghaus, Kirsten Muri Boberg, Espen Melum, Trine Folseraas, Erik Schrumpf, Annika Bergquist, Einar Björnsson, Jingyuan Fu, Harm Jan Westra, Harry J.M. Groen, Rudolf S.N. Fehrmann, Joanna Smolonska, Leonard H. van den Berg, Roel A. Ophoff, Robert J. Porte, Tobias J. Weismüller, Jochen Wedemeyer, Christoph Schramm, Martina Sterneck, Rainer Günther, Felix Braun, Severine Vermeire, Liesbet Henckaerts, Cisca Wijmenga, Cyriel Y. Ponsioen, Stefan Schreiber, Tom H. Karlsen, Andre Franke, Rinse K.

Subscribe to